Preview Mode Links will not work in preview mode

 

Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in digital health and the changing dynamic between doctors and patients.

Topics on the show include

  • the emergence of personalized medicine and breakthroughs in genomics
  • advances in biopharmaceuticals
  • age related diseases and aging in place
  • using big data from wearables and sensors
  • transparency in the medical marketplace
  • challenges for connected health entrepreneurs

The audience includes researchers, medical professionals, patient advocates, entrepreneurs, patients, caregivers, solution providers, students, journalists, and investors.

Nov 30, 2020

Daniel O'Connor, CEO, OncoSec Immunotherapies describes their intratumoral therapy where the drug is injected directly into tumors instead of a systemic treatment thereby avoiding toxicities while also seeing tumors shrink that are not being directly treated, the abscopal effect. OncoSec is using electroporation to...


Nov 30, 2020

Daniel O'Connor, CEO, OncoSec Immunotherapies describes their intratumoral therapy where the drug is injected directly into tumors instead of a systemic treatment thereby avoiding toxicities while also seeing tumors shrink that are not being directly treated, the abscopal effect. OncoSec is using electroporation to...


Nov 18, 2020

Dr. Sheri Prentiss, physician and founder LIVE Today Foundation and Rick Carreon, CEO and President, Impedimed are excited about their partnership to raise awareness about early diagnosis and treatment of lymphedema to prevent it from becoming a chronic condition. The Impedimed device conducts a simple and fast test to...


Nov 18, 2020

Dr. Sheri Prentiss, physician and founder LIVE Today Foundation and Rick Carreon, CEO and President, Impedimed are excited about their partnership to raise awareness about early diagnosis and treatment of lymphedema to prevent it from becoming a chronic condition. The Impedimed device conducts a simple and fast test to...


Oct 26, 2020

Rahul Aras, CEO, Iterion Therapeutics, describes their lead product Tegavivint, a potent selective inhibitor of nuclear beta-catenin, a high-value oncology target because of its role in cell proliferation, differentiation, immune evasion and other aspects of cancer development. An early clinical study in patients with...